Home » Authors » James Etheridge

Articles by James Etheridge

CareX Raises EUR25M in Second Round To Fund Development

March 10, 2004

By James Etheridge

CareX Brings In EUR25M To Fund Advancement Into Clinical Trials

March 9, 2004

By James Etheridge

CareX Brings In EUR25M To Fund Advancement Into Clinical Trials

March 9, 2004

By James Etheridge

Start-Up Vaxon Seeking EUR7M For Novel Cancer Vaccines

March 3, 2004

By James Etheridge

Start-Up Vaxon Seeking EUR7M For Novel Cancer Vaccines

March 3, 2004

By James Etheridge

ExonHit Raises Additional EUR8.3M; Now Has Cash To Last Into 2006

Feb. 4, 2004

By James Etheridge

ExonHit Raises Additional EUR8.3M; Now Has Cash To Last Into 2006

Feb. 4, 2004

By James Etheridge

ProSkelia, BioXell Enter Alliance To Develop Vitamin 3D Analogues

Jan. 21, 2004

By James Etheridge

Cerep Broadening Services Via $12.9M Acquisition of Hesperion

Jan. 21, 2004

By James Etheridge

ProSkelia, BioXell Enter Alliance To Develop Vitamin 3D Analogues

Jan. 21, 2004

By James Etheridge

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...